Cagrilintide vs Semaglutide

Overview

Cagrilintide is Novo Nordisk’s investigational long-acting amylin analog, while semaglutide is an approved GLP-1 receptor agonist. These peptides work through different mechanisms and are being developed as a combination therapy (CagriSema) that may provide superior weight loss to either alone.

Mechanism Comparison

Aspect	Cagrilintide	Semaglutide
Target	Amylin receptors (AMY1, AMY2, AMY3)	GLP-1 receptor
Natural Hormone	Amylin analog	GLP-1 analog
Primary Site	Area postrema (brainstem)	Hypothalamus, GI, pancreas
Half-life	~160 hours	~165 hours

Why Different Mechanisms Matter

Cagrilintide (Amylin):

• Slows gastric emptying
• Reduces glucagon secretion
• Promotes satiety via brainstem signaling
• Distinct neuronal pathways from GLP-1

Semaglutide (GLP-1):

• Enhances insulin secretion
• Suppresses glucagon
• Appetite reduction via hypothalamus
• Delays gastric emptying

These complementary mechanisms support the combination approach.

Evidence Comparison

Aspect	Cagrilintide	Semaglutide
Development Phase	Phase 3 (as CagriSema)	FDA Approved
Standalone Trials	Phase 2 completed	STEP, SUSTAIN, SELECT
Regulatory Status	Investigational	Approved
CV Outcomes Data	None	SELECT positive

Clinical Data

Cagrilintide Monotherapy (Phase 2)

Dose	Weight Loss (26 weeks)
1.2mg	~6%
2.4mg	~9%
4.5mg	~11%

Semaglutide 2.4mg (STEP 1)

Metric	Result
Weight Loss (68 weeks)	~15%
>=10% Weight Loss	69%
>=15% Weight Loss	51%

CagriSema Combination

The combination shows additive/synergistic effects:

Comparison	Weight Loss
CagriSema	~15-24% (phase 2/3 data)
Semaglutide alone	~15%
Cagrilintide alone	~11%

Regulatory Status

Aspect	Cagrilintide	Semaglutide
FDA Status	Investigational	Approved
Development Path	Primarily as CagriSema combo	Multiple indications
Expected Timeline	CagriSema 2025-2026	Already available
Standalone Pursuit	Unlikely	N/A

Administration

Aspect	Cagrilintide	Semaglutide
Route	Subcutaneous	Subcutaneous + Oral
Formulation	Single-agent or CagriSema	Ozempic, Wegovy, Rybelsus

Side Effect Profile

Effect	Cagrilintide	Semaglutide
Nausea	Common	Common
Vomiting	Common	Common
Constipation	Common	Less common
Injection Site	Reactions possible	Reactions possible

The combination (CagriSema) has higher GI event rates than either alone, though generally manageable.

Key Differences

Factor	Cagrilintide	Semaglutide
Hormone Class	Amylin	GLP-1
Primary Brain Target	Area postrema	Hypothalamus
Insulin Effect	Indirect	Direct stimulation
Standalone Efficacy	Moderate	Strong
Strategic Value	Combination partner	Standalone or backbone

The CagriSema Strategy

Novo Nordisk’s approach:

1. Combine different satiety pathways - Amylin + GLP-1
2. Maximize weight loss - Target 20%+
3. Maintain tolerability - Fixed-dose combination
4. Compete with tirzepatide - Match or exceed dual agonist efficacy

Summary

• Cagrilintide is an amylin analog with modest standalone efficacy but strategic value as a combination partner
• Semaglutide is the proven GLP-1 agonist with extensive data and CV benefit
• Different mechanisms allow additive effects when combined (CagriSema)
• CagriSema may offer weight loss comparable to or exceeding tirzepatide
• Cagrilintide is unlikely to be marketed as standalone therapy

---

This comparison is for educational purposes only. Cagrilintide is investigational. Consult a healthcare provider for treatment decisions.